M
Maxime Dougados
Researcher at University of Paris
Publications - 1144
Citations - 78022
Maxime Dougados is an academic researcher from University of Paris. The author has contributed to research in topics: Rheumatoid arthritis & Ankylosing spondylitis. The author has an hindex of 134, co-authored 1054 publications receiving 69979 citations. Previous affiliations of Maxime Dougados include French Institute of Health and Medical Research & Paris Descartes University.
Papers
More filters
Journal ArticleDOI
EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees
Maxime Dougados,Neil Betteridge,Gerd-Rüdiger Burmester,Liana Euller-Ziegler,Francis Guillemin,J Hirvonen,J Lloyd,Seza Ozen,J. A. P. Da Silva,Paul Emery,J. R. Kalden,T K Kvien,Marco Matucci-Cerinic,Josef S. Smolen +13 more
TL;DR: It is the opinion of the EULAR executive committee members that “guidelines” might appear too constraining and that, on the other hand, “points to consider’ might be considered as too open.
Journal ArticleDOI
Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
Peter Brooks,Paul Emery,J F Evans,H Fenner,Christopher J. Hawkey,C Patrono,Josef S. Smolen,F. C. Breedveld,Richard O. Day,Maxime Dougados,E W Ehrich,J Gijon-Baños,T.K. Kvien,M. H. Van Rijswijk,Timothy D. Warner,Henning Zeidler +15 more
TL;DR: The International Consensus Meeting on the Mode of Action of COX-2 Inhibition (ICMMAC) brought together 17 international experts in arthritis, gastroenterology and pharmacology to foster a consensus definition on COx-2 specificity and to consider the clinical relevance of COZ-2-specific agents.
Journal ArticleDOI
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde,James Cheng-Chung Wei,Maxime Dougados,Philip J. Mease,Atul Deodhar,Walter P. Maksymowych,Filip Van den Bosch,Joachim Sieper,Tetsuya Tomita,Robert Landewé,Fangyi Zhao,Eswar Krishnan,David H. Adams,Beth A. Pangallo,Hilde Carlier,Melvin Churchill,Kathleen P. Flint,Geoffrey Gladstein,Maria Greenwald,Mary P. Howell,Akgun Ince,Jeffrey L. Kaine,Daksha Mehta,Eric A. Peters,Roel Querubin,John D. Reveille,Richard Roseff,Roger J. Diegel,Christine Thai,Louis Bessette,Frederic Morin,Proton Rahman,Aaron Alejandro Barrera Rodriguez,Fidencio Cons-Molina,Sergio Duran Barragan,Cassandra M. Skinner,Cesar Francisco Pacheco Tena,Cesar Ricardo Ramos Remus,Juan Cruz Rizo Rodriguez,Seung-Jae Hong,Yeon-Ah Lee,Ji Hyeon Ju,Seong Wook Kang,Tae-Hwan Kim,Chang Keun Lee,Eun Bong Lee,Sang-Heon Lee,Min Chan Park,Kichul Shin,Sang-Hoon Lee,Hung-An Chen,Ying-Chou Chen,Song-Chou Hsieh,Joung-Liang Lan,Zdenek Dvorak,Radka Moravcova,Martina Malcova,Yoshinori Taniguchi,Mitsumasa Kishimoto,Kurisu Tada,Hiroaki Dobashi,Kentaro Inui,Yukitaka Ueki,Yoshifuji Matsumoto,Yoshinobu Koyama,Kazuhiro Hatta,Tatsuya Atsumi,Hitoshi Goto,Kiyoshi Matsui,Yuya Takakubo,Gunther Neeck,Denis Poddubnyy,Andrea Rubbert-Roth,Malgorzata Szymanska,Tomasz Blicharski,Anna Dudek,Artur Racewicz,Rafal Wojciechowski,Marleen G H van de Sande,Ed Griep,Michael T. Nurmohamed,Galina Matsievskaya,Evgeniya Shmidt,Marina Stanislav,Sergey Yakushin,Olga Ershova,A P Rebrov,Tibor Balazs,Regina Cseuz,E. Drescher,Gyula Poor +90 more
TL;DR: Each dosing regimen of ixekizumab was superior to placebo for improving radiographic axial spondyloarthritis signs and symptoms in patients not previously treated with bDMARDs; the safety profile was consistent with previous indications of IXekzumab.
Journal ArticleDOI
Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.
Désirée van der Heijde,Herbert S B Baraf,Cesar Ramos-Remus,Andrei Calin,Arthur L. Weaver,Michael Schiff,Margaret James,Jan E Markind,Alise S. Reicin,Agustin Melian,Maxime Dougados +10 more
TL;DR: Etoricoxib at doses of 90 mg and 120 mg demonstrated superior efficacy compared with placebo over 6 weeks, and compared with naproxen over 1 year, demonstrating that etoricoxIB is generally safe, well-tolerated, and efficacious for the treatment of AS.
Journal ArticleDOI
The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients.
Maxime Dougados,Maria Antonietta D'Agostino,Joelle Benessiano,Francis Berenbaum,Maxime Breban,Pascal Claudepierre,Bernard Combe,Patricia Dargent-Molina,Jean-Pierre Daurès,Bruno Fautrel,Antoine Feydy,Philippe Goupille,Véronique Leblanc,Isabelle Logeart,Thao Pham,Pascal Richette,Christian Roux,Martin Rudwaleit,Alain Saraux,Jean-Marc Tréluyer,Désirée van der Heijde,D. Wendling +21 more
TL;DR: This large cohort of patients presenting with early inflammatory back pain should facilitate the conduct of researches in different areas (clinical, medico-economics, translational) in order to improve knowledge on the pathogenesis and natural history of axial spondyloarthritis.